Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Jean James

Nurse Practitioner Los Angeles, CA Nurse Practitioner

NPI 1902932700 CMS profile 10491364

12021 Wilmington Ave, Los Angeles, CA 90059

Open in the dashboard

General payments

$20,852

83 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Jean James of Los Angeles, CA is reported in the CMS Open Payments database as having received $20,852 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $11,029 41
2022 General $5,409 22
2021 General $4,413 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jean James
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jean James were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jean James Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $4,413 $135 $40–$426 $132
2022 $5,409 $152 $48–$470 $149
2023 $11,029 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Gilead Sciences, Inc. $11,184 47 payments
  2. ViiV Healthcare Company $9,324 21 payments
  3. Janssen Biotech, Inc. $135 5 payments
  4. Merck Sharp & Dohme Corporation $82 4 payments
  5. EMD Serono, Inc. $44 2 payments
  6. Pfizer Inc. $43 2 payments
  7. Janssen Pharmaceuticals, Inc $28 1 payment
  8. Organon LLC $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,220 13 payments
  2. Consulting Fee $5,700 2 payments
  3. Travel and Lodging $3,061 10 payments
  4. Food and Beverage $1,842 57 payments
  5. Education $28 1 payment
Products named General payments · program years 2021–2023
  1. Biktarvy $6,557 13 payments
  2. DOVATO $6,230 12 payments
  3. SYMTUZA $135 5 payments
  4. PIFELTRO $66 3 payments
  5. DELSTRIGO $66 3 payments
  6. PREVNAR 20 $43 2 payments
  7. COMIRNATY $21 1 payment
  8. PAXLOVID $21 1 payment
  9. ISENTRESS $20 1 payment
  10. GARDASIL 9 $16 1 payment
  11. Other $44 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record